Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    11
    ...
ATC Name B/G Ingredients Dosage Form Price
N07X CEREBROLYSIN G Cerebrolysin - 215.2mg/ml 215.2mg/ml Injectable concentrated solution 2,303,346 L.L
N07X CEREBROLYSIN G Cerebrolysin - 215.2mg/ml 215.2mg/ml Injectable concentrated solution 3,886,393 L.L
N02BE01 CHILDREN'S PANADOL 5-12 YEARS B Paracetamol - 240mg/5ml 240mg/5ml Elixir 356,118 L.L
R03BA01 CLENIL 250 MCG SPRAY B Beclometasone dipropionate - 250mcg/actuation 250mcg/actuation Inhalation solution 1,166,455 L.L
R03BA01 CORTIS G Beclometasone dipropionate - 250mcg/actuation 250mcg/actuation Inhalation solution 674,609 L.L
H05AA02 CINNOPAR BioTech Teriparatide - 250mcg/ml 250mcg/ml Injectable solution 15,275,833 L.L
N02BE51 COQUELUSEDAL PARACETAMOL G Paracetamol - 250mg, Grindelia extract - 20mg, Gelsenium extract - 10mg 250mg Suppository 578,623 L.L
A12AA04 CI-CAL B Calcium citrate - 250mg 250mg Tablet 555,007 L.L
J01BA01 CHLORAMPHENICOL G Chloramphenicol - 250mg 250mg Capsule 166,381 L.L
J01FA09 CLAREM 250 G Clarithromycin - 250mg 250mg Tablet, film coated 467,657 L.L
J01FA09 CLAMYCIN G Clarithromycin - 250mg 250mg Tablet, film coated 641,205 L.L
L04AA06 CELLCEPT B Mycophenolate mofetil - 250mg 250mg Capsule 6,083,575 L.L
J01FA09 CLARIDAR DAR AL DAWA G Clarithromycin - 250mg/5ml 250mg/5ml Suspension 877,529 L.L
J01DB05 CEFADRIL G Cefadroxil (monohydrate) - 250mg/5ml 250mg/5ml Powder for suspension 268,769 L.L
J01DC04 CECLOR B Cefaclor (monohydrate) - 250mg/5ml 250mg/5ml Granules for suspension 851,100 L.L
J01DC04 CLORACEF FORTE G Cefaclor (monohydrate) - 250mg/5ml 250mg/5ml Powder for suspension 632,950 L.L
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 712,237 L.L
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 1,343,843 L.L
C07AG02 CARVEDILOL ARROW G Carvedilol - 25mg 25mg Tablet, film coated, scored 425,998 L.L
C09AA01 CAPTACE G Captopril - 25mg 25mg Tablet, scored 486,343 L.L
C09AA01 CAPTOPRIL G Captopril - 25mg 25mg Tablet, scored 4,453,878 L.L
C09AA01 CAPTOPRIL G Captopril - 25mg 25mg Tablet, scored 355,798 L.L
N06BA04 CONCERTA B Methylphenidate HCl - 27mg 27mg Tablet, extended release 4,393,021 L.L
C01DX12 CORVASAL 2MG B Molsidomine - 2mg 2mg Tablet, scored 398,033 L.L
C01DX12 CORVASAL 2MG B Molsidomine - 2mg 2mg Tablet, scored 1,092,992 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 2mg 2mg Tablet, film coated 2,956,454 L.L
C09CA04 CONVERIUM G Irbesartan - 300mg 300mg Tablet 585,915 L.L
N03AG01 CONVULEX G Sodium Valproate - 300mg/ml 300mg/ml Solution 1,018,633 L.L
L03AB07 CINNOVEX BioTech Interferon beta-1a - 30mcg 30mcg Injectable solution 39,804,728 L.L
H05BX01 CINACALCET ARROW BioTech Cinacalcet - 30mg 30mg Tablet, coated 8,768,039 L.L
    ...
    11
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025